| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eb9c6b40161bafe7bd55f0b4defcea04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bcff13f8573db698307f919e6385d5c4 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S530-808
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S530-806 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2845
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-91 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-02 |
| filingDate |
1988-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6855aafbeb4334acd41ad7389317daab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3b9ad35547e63a005de4bae7035ccd6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aebb611b9a6e7413ebaa398d95e51dab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0043bd438812a30e454253d3ed364f9c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_49fdb87abcf24e46fcdb77d740b9f335 |
| publicationDate |
1988-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-8809672-A1 |
| titleOfInvention |
Method of reducing tissue damage at an inflammatory site using a monoclonal antibody |
| abstract |
A method of reducing tissue injury in humans or other animal species using a monoclonal antibody to inhibit specific phagocyte functions. The monoclonal antibody is selected to bind to phagocytic leukocytes for the purpose of inhibiting migration to an inflammatory site in the body and to inhibit the adhesion and spreading of activated leukocytes reaching such an area and then, block release of toxic substances by these cells. The monoclonal antibody is administered $i(in vivo) prior or early in the course of an experience leading to an injurious inflammatory response such as can result from restoration of myocardial blood flow interrupted by an acute coronary thrombosis. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5340800-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0670734-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0670734-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4986979-A |
| priorityDate |
1987-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |